Pre-transplant administration of IL-25 has been shown to safeguard cuprocytes from GVHD, mitigate bacterial translocation, lower plasma levels of IFN-γ and IL-6, and alleviate symptoms associated with GVHD. Here, IFNG is linked to graft versus host disease.